US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

13.49

-0.0300-0.22%

Post-market: 13.490.00000.00%19:53 EST

Volume:540.91K

Turnover:7.26M

Market Cap:422.10M

PE:-6.40

High:13.73

Open:13.50

Low:13.14

Close:13.52

52wk High:50.40

52wk Low:11.48

Shares:31.29M

Float Shares:15.69M

Volume Ratio:0.70

T/O Rate:3.45%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1087

EPS(LYR):-2.3387

ROE:-28.78%

ROA:-19.52%

PB:2.18

PE(LYR):-5.77

Loading ...

Overview Company News Filings

Summit Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026

Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference

Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Press Release: Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Transcenta Therapeutics to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

GSK Signs Exclusive Global Licensing Agreement With Frontier Biotech for RNA Therapeutics

MT Newswires Live

Citi adds ‘upside 90-day catalyst watch’ on Summit Therapeutics

Assessing CARsgen Therapeutics Holdings (SEHK:2171) Valuation After New CAR T-Cell Manufacturing Partnership

Simply Wall St.

Lenz Therapeutics Publishes Corporate Presentation on VIZZ Presbyopia Eye Drop Commercialization

PYC Therapeutics Issues Cautious Q1 2026 Investor Update

PYC Therapeutics Shares Flat As It Posts Narrower Fiscal H1 Loss, Lower Revenue

MT Newswires Live

Avenue Therapeutics Licenses ATX-04 for Pompe Disease

Summit Therapeutics Reports 2025 Results, Advances Ivonescimab Programs

Denali Therapeutics initiated with a Peer Perform at Wolfe Research

Summit Therapeutics reports Q4 adjusted EPS (14c), consensus (1c)

Summit Therapeutics Q4 Adj. EPS $(0.14) Misses $(0.07) Estimate

Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LENZ/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":13.49,"timestamp":1772226000000,"preClose":13.52,"halted":0,"volume":540909,"hourTrading":{"tag":"盘后","latestPrice":13.49,"preClose":13.49,"latestTime":"19:53 EST","volume":99213,"amount":1338366.7596,"timestamp":1772240000613,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0022189349112425563,"floatShares":15692500,"shares":31289969,"eps":-2.10871,"marketStatus":"Market Closed","change":-0.03,"latestTime":"02-27 16:00:00 EST","open":13.5,"high":13.73,"low":13.14,"amount":7263659.251944,"amplitude":0.043639,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.10871,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":13.52,"postHourTrading":{"tag":"盘后","latestPrice":13.49,"preClose":13.49,"latestTime":"19:53 EST","volume":99213,"amount":1338366.7596,"timestamp":1772240000613,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6979926191889101,"impliedVol":0.9544,"impliedVolPercentile":0.6592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":15692500,"roa":"-19.52%","roe":"-28.78%","lyrEps":-2.338654,"volumeRatio":0.6979926191889101,"shares":31289969,"dividePrice":0,"high":13.73,"amplitude":0.043639,"preClose":13.52,"low":13.14,"week52Low":11.48,"pbRate":"2.18","psRate":"24.12","week52High":50.4,"institutionHeld":0,"latestPrice":13.49,"eps":-2.10871,"divideRate":0,"volume":540909,"delay":0,"ttmEps":-2.10871,"open":13.5,"prevYearClose":16,"prevWeekClose":11.59,"prevMonthClose":15.82,"prevQuarterClose":16,"fiveDayClose":11.59,"twentyDayClose":17.78,"sixtyDayClose":30.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59},{"market":"US","date":"2025-07-30","symbol":"LENZ","fiscalQuarterEnding":"2025/06","expectedEps":-0.58,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1753848000000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53},{"market":"US","date":"2024-03-22","symbol":"LENZ","defaultRemindTime":1711114200000,"type":"split","dateTimestamp":1711080000000,"forFactor":7,"toFactor":1,"ratio":7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5714,"buy":0.4286,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5714,"analysts":7,"updateTime":1742706000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-02-27","current":-6.397276,"percent":0.855292,"low":-26.69966,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"high":-5.069183,"avg":-12.746789,"sd":5.133348,"marketCap":423040380},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380}],"updateTime":1772275201521},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613716594","title":"Summit Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2613716594","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613716594?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:14","pubTimestamp":1771935240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SMMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2026 07:14 ET (12:14 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMF","LENZ"],"gpt_icon":0},{"id":"2613559719","title":"Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613559719","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613559719?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:01","pubTimestamp":1771934460,"startTime":"0","endTime":"0","summary":"New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM304 Anticipated in 2026 Updated Phase 1/2 Data and Next St","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/24/3243386/0/en/Beam-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Announces-New-Liver-Targeted-Genetic-Disease-Program-in-Phenylketonuria-PKU.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","BK4533","BEAM","BK4535","BK4585","LU0225284248.USD","LU0289739699.SGD","LU0868494617.USD","LU1894683264.USD","BK4505","SGXZ57979304.SGD","BK4599","SG9999011175.SGD","LU0306806265.USD","LU0306807586.USD","LU0170899867.USD","LU1894683348.USD","SG9999001176.USD","BK4534","LENZ","SG9999013999.USD","LU0321505868.SGD","LU1023059063.AUD","BK4568","LU1861559042.SGD","IND","LU1883839398.USD","BK4539","IE000M9KFDE8.USD","LU0122379950.USD","BK4588","BK4556","LU1066051498.USD","SG9999001176.SGD","SG9999002224.SGD","BK4611","SG9999002232.USD","LU0456855351.SGD","LU0321505439.SGD","LU1861558580.USD","IE00BBT3K403.USD","BK4139","ASH","BK4581","BK4550","LU0234572021.USD","SCD","BK4592","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2613719586","title":"Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613719586","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613719586?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:00","pubTimestamp":1771934400,"startTime":"0","endTime":"0","summary":"Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label studyFDA written communic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/24/3243356/0/en/Larimar-Therapeutics-Announces-FDA-Breakthrough-Therapy-Designation-for-Nomlabofusp-in-FA-and-Reiterates-Planned-BLA-Submission-in-June-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","CEO","FXN","BK4539","FA","BK4130","BK4139","BK4535"],"gpt_icon":0},{"id":"2613719397","title":"Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2613719397","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613719397?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:00","pubTimestamp":1771934400,"startTime":"0","endTime":"0","summary":"NEW YORK and WALTHAM, Mass., Feb.  24, 2026  (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/24/3243371/0/en/Dianthus-Therapeutics-to-Participate-in-The-TD-Cowen-46th-Annual-Health-Care-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BK4207","XBI","LABU","LENZ","TD","BK4539","COWN","BK4581","BK4588","BK4127","BK4585","BK4007","BK4139","XLV"],"gpt_icon":0},{"id":"2613719394","title":"Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2613719394","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613719394?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:00","pubTimestamp":1771934400,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Feb.  24, 2026  (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improveme","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/24/3243338/0/en/Aquestive-Therapeutics-to-Report-Fourth-Quarter-2025-Financial-Results-and-Recent-Business-Highlights-on-March-4-and-Host-Conference-Call-on-March-5-at-8-00-a-m-ET.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4181","BK4581","CDMO","BK4218","BK4139","AQST","HST","ET","BK4007","BK4590","BK4561","LENZ","BK4588","BK4585","BK4144"],"gpt_icon":0},{"id":"2613719348","title":"Avalo Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2613719348","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613719348?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:00","pubTimestamp":1771934400,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., Feb.  24, 2026  (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/24/3243376/0/en/Avalo-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","LENZ","BK4539"],"gpt_icon":0},{"id":"2613571540","title":"Press Release: Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2613571540","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613571540?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:00","pubTimestamp":1771934400,"startTime":"0","endTime":"0","summary":"$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term. Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated Launch of Risto-cel in Sickle Cell Disease . The credit facility matures in early 2033 and bears interest at an annual rate of approximately 10% based on current forward projections for SOFR. The facility does not provide for scheduled amortization payments, and all principal amounts will be due at maturity in early 2033. Beam may prepay loans under the credit facility at any time, subject to customary yield maintenance and prepayment premiums during the early years of the facility. The company is expecting to draw a minimum of $200 million of capital under the overall facility and make mandatory prepayments from certain non-ordinary course proceeds, including proceeds from non-permit","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAM","BK4505","BK4539","BK4585","SCD","BK4588","BK4535","BK4007","BK4139","LU1861558580.USD","LU1861559042.SGD","BK4611","BK4556","LENZ"],"gpt_icon":0},{"id":"2613560719","title":"Transcenta Therapeutics to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2613560719","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613560719?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:00","pubTimestamp":1771934400,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J. and SUZHOU, China, Feb.  24, 2026  (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) (\"Transcenta Therapeutics\"), a global clinical stage biopharmaceutical company with full","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/24/3243379/0/en/Transcenta-Therapeutics-to-Present-at-the-36th-Annual-Oppenheimer-Healthcare-Life-Sciences-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874061.USD","OPY","XBI","BK4539","BK4139","XLV","BK4585","LABU","BK4581","LENZ","LU0128526141.USD","BK4137","BK4127","BK4588","HCSG","BK4007"],"gpt_icon":0},{"id":"2613713989","title":"GSK Signs Exclusive Global Licensing Agreement With Frontier Biotech for RNA Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2613713989","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613713989?lang=en_us&edition=fundamental","pubTime":"2026-02-24 19:43","pubTimestamp":1771933390,"startTime":"0","endTime":"0","summary":"GSK  established an exclusive global licensing deal with Frontier Biotech to develop and commercialize two small interfering RNA drug candidates, Frontier Biotech said Tuesday.The agreement has a $40 million upfront payment, alongside up to $963 million based on regulatory and commercial milestones, along with tiered global royalties based on worldwide net sales, the companies said.The transaction grants the biopharmaceutical company worldwide rights to a preclinical asset and another treatment currently at the investigational new drug stage, they said.The biotechnology firm will manage early-stage testing in China before GSK assumes control of all subsequent worldwide clinical, regulatory, and commercialization efforts, they added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","FTR","GSK.UK","IE0009354923.USD","RNA","GSK","LABU","BK4505","LENZ","BK4539","RNAM","BK4588","LU1829250122.USD","BK4585","BK4007","BK4139","GSKH"],"gpt_icon":0},{"id":"2613790652","title":"Citi adds ‘upside 90-day catalyst watch’ on Summit Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2613790652","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613790652?lang=en_us&edition=fundamental","pubTime":"2026-02-24 18:50","pubTimestamp":1771930236,"startTime":"0","endTime":"0","summary":"Citi analyst Yigal Nochomovitz placed an “upside 90-day catalyst watch” on shares of Summit Therapeutics (SMMT) while keeping a Buy rating on the n...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citi-adds-upside-90-day-catalyst-watch-on-summit-therapeutics-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citi-adds-upside-90-day-catalyst-watch-on-summit-therapeutics-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4211","SMMT","LU2488822045.USD","BK4007","BK4139","SMMF"],"gpt_icon":0},{"id":"2613793010","title":"Assessing CARsgen Therapeutics Holdings (SEHK:2171) Valuation After New CAR T-Cell Manufacturing Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2613793010","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613793010?lang=en_us&edition=fundamental","pubTime":"2026-02-24 12:51","pubTimestamp":1771908706,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings (SEHK:2171) has entered new cooperation agreements to build a commercial CAR T-cell manufacturing base in Shanghai’s Jinshan District, supporting its existing therapies, late-stage candidates and future allogeneic products.\nSee our latest analysis for CARsgen Therapeutics Holdings.\nThe cooperation news lands as CARsgen’s share price sits at HK$16.14, with a 1-day share price return of 3.33% and 7-day share price return of 7.10%. The 1-year total shareholder...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/assessing-carsgen-therapeutics-holdings-sehk2171-valuation-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/assessing-carsgen-therapeutics-holdings-sehk2171-valuation-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","LENZ","BK4022","BK4007","02171","BK1587","BK4139","CAR","BK1161","BK4230","BK4539","BK1585"],"gpt_icon":0},{"id":"2613523937","title":"Lenz Therapeutics Publishes Corporate Presentation on VIZZ Presbyopia Eye Drop Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2613523937","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613523937?lang=en_us&edition=fundamental","pubTime":"2026-02-24 09:35","pubTimestamp":1771896946,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics Inc. highlighted the commercial rollout of VIZZ, an FDA-approved prescription eye drop for presbyopia designed to improve near vision with once-daily dosing. The company said VIZZ launched in October 2025 and is widely available, supported by a sales team of more than 100 representatives targeting approximately 15,000 eye care professionals and a direct-to-consumer campaign featuring Sarah Jessica Parker. The presentation also summarized clinical data from the CLARITY studies indicating rapid onset and durability of near-vision improvement for up to 10 hours, and noted tolerability observations including no serious treatment-related adverse events reported in trials. Pricing details included $79 for a one-month supply  and $198 for a three-month supply , with cash-pay access and HSA/FSA eligibility. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL1pD8wY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LENZ","BK4539","BK4139"],"gpt_icon":0},{"id":"2613756294","title":"PYC Therapeutics Issues Cautious Q1 2026 Investor Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2613756294","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613756294?lang=en_us&edition=fundamental","pubTime":"2026-02-24 07:45","pubTimestamp":1771890348,"startTime":"0","endTime":"0","summary":"PYC Therapeutics Limited ( ($AU:PYC) ) just unveiled an update. PYC Therapeutics has released a Q1 2026 investor update outlining the status of its...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-issues-cautious-q1-2026-investor-update?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-issues-cautious-q1-2026-investor-update?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4007","BK4139"],"gpt_icon":0},{"id":"2613756538","title":"PYC Therapeutics Shares Flat As It Posts Narrower Fiscal H1 Loss, Lower Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2613756538","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613756538?lang=en_us&edition=fundamental","pubTime":"2026-02-24 07:40","pubTimestamp":1771890033,"startTime":"0","endTime":"0","summary":"Shares of PYC Therapeutics  were flat in early trading on Tuesday after it reported late Monday a fiscal first-half loss of AU$0.0391 per share, compared with AU$0.0548 a year earlier.Revenue for the six months ended Dec. 31, 2025, was AU$11 million, compared with AU$12.7 million a year earlier.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"gpt_icon":0},{"id":"2613075882","title":"Avenue Therapeutics Licenses ATX-04 for Pompe Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2613075882","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613075882?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:39","pubTimestamp":1771882781,"startTime":"0","endTime":"0","summary":"Avenue Therapeutics ( ($ATXI) ) has issued an update. On February 23, 2026, Avenue Therapeutics announced it had entered an exclusive worldwide lic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/avenue-therapeutics-licenses-atx-04-for-pompe-disease?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/avenue-therapeutics-licenses-atx-04-for-pompe-disease?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","BK4007","LENZ"],"gpt_icon":0},{"id":"2613758816","title":"Summit Therapeutics Reports 2025 Results, Advances Ivonescimab Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2613758816","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613758816?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:36","pubTimestamp":1771882614,"startTime":"0","endTime":"0","summary":"Summit Therapeutics ( ($SMMT) ) has shared an announcement. On February 23, 2026, Summit Therapeutics reported its fourth-quarter and full-year 202...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/summit-therapeutics-reports-2025-results-advances-ivonescimab-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/summit-therapeutics-reports-2025-results-advances-ivonescimab-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SMMF","BK4539","BK4139","BK4211","LENZ","BK4007"],"gpt_icon":0},{"id":"2613321730","title":"Denali Therapeutics initiated with a Peer Perform at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2613321730","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613321730?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:17","pubTimestamp":1771881471,"startTime":"0","endTime":"0","summary":"Wolfe Research analyst Rudy Li initiated coverage of Denali Therapeutics (DNLI) with a Peer Perform rating and no price target The firm launched co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/denali-therapeutics-initiated-with-a-peer-perform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/denali-therapeutics-initiated-with-a-peer-perform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","DNLI","BK4539","BK4535","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2613379730","title":"Summit Therapeutics reports Q4 adjusted EPS (14c), consensus (1c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613379730","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613379730?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:10","pubTimestamp":1771881016,"startTime":"0","endTime":"0","summary":"“We provide the following updates for the global Phase III HARMONi-3 clinical trial: For the HARMONi-3 squamous cohort: Screening by investigators ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-reports-q4-adjusted-eps-14c-consensus-1c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-reports-q4-adjusted-eps-14c-consensus-1c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","SMMF"],"gpt_icon":0},{"id":"2613371157","title":"Summit Therapeutics Q4 Adj. EPS $(0.14) Misses $(0.07) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2613371157","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613371157?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:07","pubTimestamp":1771880833,"startTime":"0","endTime":"0","summary":"Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.07) by 89.19 percent. This is a 100 percent decrease over losses of $(0.07) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50798589/summit-therapeutics-q4-adj-eps-0-14-misses-0-07-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SMMF"],"gpt_icon":0},{"id":"2613415730","title":"Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2613415730","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613415730?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:05","pubTimestamp":1771880700,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif., Feb.  23, 2026  (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/23/3243026/0/en/Metagenomi-Therapeutics-Inc-to-Present-at-the-46th-Annual-TD-Cowen-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LENZ","XBI","COWN","BK4139","BK4007","LU0128526141.USD","LU0029874061.USD","BK4585","BK4207","MGX","HCSG","BK4127","BK4581","TD","BK4566","XLV","BK4539","BK4137","LABU"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}